Drug intelligence / Profile preview

IPG6620

Development stage: Preclinical
Lead developer: Nanjing Immunophage Biotech
Modality: Small Molecules

Overview

IPG6620 is a small molecule antagonist of the Lysophosphatidic acid receptor 5 (LPAR5), also known as GPR92, currently in preclinical development by Nanjing Immunophage Biotech. It is being investigated for the treatment of chemotherapy-induced peripheral neuropathy (CIPN). LPAR5 is a G protein-coupled receptor that is highly expressed in sensory neurons and has been identified as a key mediator of neuropathic pain signaling. By blocking LPAR5, IPG6620 aims to inhibit the pro-nociceptive pathways activated by lysophosphatidic acid (LPA), thereby reducing the pain and sensory deficits associated with nerve damage caused by cytotoxic chemotherapy agents.

Targets

LPAR5 (Lysophosphatidic acid receptor 5)

Beyond the preview

Go deeper on IPG6620.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IPG6620.

Explore the full profile